Research programme: kinase inhibitors - Evotec AG/Nycomed
Latest Information Update: 11 Aug 2008
At a glance
- Originator Evotec AG; Nycomed
- Developer Nycomed
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 02 Apr 2008 Preclinical development is ongoing
- 12 Oct 2004 Preclinical trials in Undefined in Germany (unspecified route)